Protocol Ledger

NCT05409066 · Phase III · ACTIVE NOT RECRUITING

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma

Interventional Phase III clinical trial protocol NCT05409066 sponsored by Genmab in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-09-20 Enrollment: 549 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05409066
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)549 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05409066
Protocol FieldVerified Registry Value
NCT IdentifierNCT05409066
Consolidated Lead SponsorGenmab
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment549 participants (ACTUAL)
Registered Start Date2022-09-20
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI